https://www.defense.gov/Newsroom/Contracts/Contract/Article/2471330//

Contract awarded on the 12th, announced yesterday.

Regeneron Pharmaceuticals Inc., Tarrytown, New York, was awarded a $2,625,000,000 firm-fixed-price contract for 1.25 million courses of a monoclonal antibody therapeutic (a combination of casirivimab and imdevimab) for COVID-19. Bids were solicited via the internet with one received. Work will be performed in Tarrytown, New York, with an estimated completion date of Jan. 11, 2022. Fiscal 2022 research, development, test and evaluation (Army) funds in the amount of $2,625,000,000 were obligated at the time of the award. U.S. Army Contracting Command, Newark, New Jersey, is the contracting activity (W15QKN-21-C-0014). (Awarded Jan. 12, 2021)